Relationship between androgen deprivation therapy and community-acquired respiratory infections in patients with prostate cancer

International Journal of Urology

Volumn 23, Issue 4, 2016, Pages 305-311

  Schmid, Marianne ^a,b   Hanske, Julian ^a,c   Ravi, Praful ^d   Krishna, Nandita ^a   Reznor, Gally ^a   Meyer, Christian P ^a,b   Fisch, Margit ^b   Noldus, Joachim ^c   Nguyen, Paul L ^a   Trinh, Quoc Dien ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^c RUHR UNIVERSITY BOCHUM   (Germany)

^d MAYO CLINIC   (United States)

Author keywords

Androgen deprivation therapy; Pneumonia; Prostate cancer; Respiratory infections; Surveillance, Epidemiology and End Results Medicare

Indexed keywords

GONADORELIN AGONIST; ANTIANDROGEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

ACUTE SINUSITIS; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; BRONCHITIS; CANCER PATIENT; CANCER SURGERY; COMMUNITY ACQUIRED INFECTION; CONTROLLED STUDY; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; ORCHIECTOMY; PNEUMONIA; PRIORITY JOURNAL; PROSTATE CANCER; RESPIRATORY TRACT INFECTION; COHORT ANALYSIS; COMMUNITY-ACQUIRED INFECTIONS; PROPORTIONAL HAZARDS MODEL; PROSTATIC NEOPLASMS; RESPIRATORY TRACT INFECTIONS; RETROSPECTIVE STUDY; RISK; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; COHORT STUDIES; COMMUNITY-ACQUIRED INFECTIONS; HUMANS; MALE; ORCHIECTOMY; PROPORTIONAL HAZARDS MODELS; PROSTATIC NEOPLASMS; RESPIRATORY TRACT INFECTIONS; RETROSPECTIVE STUDIES; RISK;

EID: 84954305169     PISSN: 09198172     EISSN: 14422042     Source Type: Journal    
DOI: 10.1111/iju.13043     Document Type: Article

References (31)

1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J. Clin. 2014; 64: 9-29.
2. Shahinian VB, Kuo YF, Gilbert SM. Reimbursement policy and androgen-deprivation therapy for prostate cancer. N. Engl. J. Med. 2010; 363: 1822-32.
3. Bastian PJ, Boorjian SA, Bossi A et al. High-risk prostate cancer: from definition to contemporary management. Eur. Urol. 2012; 61: 1096-106.
4. Mohler JL, Armstrong AJ, Bahnson RR et al. Prostate cancer, Version 3.2012: featured updates to the NCCN guidelines. J. Natl. Compr. Canc. Netw. 2012; 10: 1081-7.
5. Singer EA, Golijanin DJ, Miyamoto H, Messing EM. Androgen deprivation therapy for prostate cancer. Expert Opin. Pharmacother. 2008; 9: 211-28.
6. Lu-Yao GL, Albertsen PC, Moore DF et al. Fifteen-year survival outcomes following primary androgen-deprivation therapy for localized prostate cancer. JAMA Intern. Med. 2014; 174: 1460-7.
7. Gandaglia G, Sun M, Hu JC et al. Gonadotropin-releasing hormone agonists and acute kidney injury in patients with prostate cancer. Eur. Urol. 2014; 66: 1125-32.
8. Hu JC, Williams SB, O'Malley AJ, Smith MR, Nguyen PL, Keating NL. Androgen-deprivation therapy for nonmetastatic prostate cancer is associated with an increased risk of peripheral arterial disease and venous thromboembolism. Eur. Urol. 2012; 61: 1119-28.
9. Keating NL, O'Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J. Clin. Oncol. 2006; 24: 4448-56.
10. Shao YH, Moore DF, Shih W, Lin Y, Jang TL, Lu-Yao GL. Fracture after androgen deprivation therapy among men with a high baseline risk of skeletal complications. BJU Int. 2013; 111: 745-52.
11. Schmid M, Sammon JD, Reznor G et al. Dose-dependent effect of androgen deprivation therapy for localized prostate cancer on adverse cardiac events. BJU Int. 2015; doi: 10.1111/bju.13203.
12. U.S. Food and Drug Administration. [Cited 15 Jun 2015]. Available from URL: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2010/ucm210549.htm
13. Garcia-Gomez E, Gonzalez-Pedrajo B, Camacho-Arroyo I. Role of sex steroid hormones in bacterial-host interactions. Biomed Res. Int. 2013; 2013: 928290.
14. Klein SL. The effects of hormones on sex differences in infection: from genes to behavior. Neurosci. Biobehav. Rev. 2000; 24: 627-38.
15. Plotkin BJ, Roose RJ, Erikson Q, Viselli SM. Effect of androgens and glucocorticoids on microbial growth and antimicrobial susceptibility. Curr. Microbiol. 2003; 47: 514-20.
16. Morrison VA. An overview of the management of infection and febrile neutropenia in patients with cancer. Support. Cancer Ther. 2005; 2: 88-94.
17. Chung SD, Liu SP, Lin HC, Wang LH. Increased risk of pneumonia in patients receiving gonadotropin-releasing hormone agonists for prostate cancer. PLoS ONE 2014; 9: e101254.
18. Warren JL, Klabunde CN, Schrag D, Bach PB, Riley GF. Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med. Care 2002; 40: IV-3-18.
19. Shahinian VB, Kuo YF, Freeman JL, Goodwin JS. Risk of fracture after androgen deprivation for prostate cancer. N. Engl. J. Med. 2005; 352: 154-64.
20. Wong YN, Mitra N, Hudes G et al. Survival associated with treatment vs observation of localized prostate cancer in elderly men. JAMA 2006; 296: 2683-93.
21. Klabunde CN, Potosky AL, Legler JM, Warren JL. Development of a comorbidity index using physician claims data. J. Clin. Epidemiol. 2000; 53: 1258-67.
22. Lindenauer PK, Lagu T, Shieh MS, Pekow PS, Rothberg MB. Association of diagnostic coding with trends in hospitalizations and mortality of patients with pneumonia, 2003-2009. JAMA 2012; 307: 1405-13.
23. Smith MR, Lee H, Nathan DM. Insulin sensitivity during combined androgen blockade for prostate cancer. J. Clin. Endocrinol. Metab. 2006; 91: 1305-8.
24. Cooksley CD, Avritscher EB, Rolston KV, Elting LS. Hospitalizations for infection in cancer patients: impact of an aging population. Support. Care Cancer 2009; 17: 547-54.
25. Ojeda MS, Gomez NN, Gil E, Scardapane L, Gimenez MS. Morphologic and biochemical changes in male rat lung after surgical and pharmacological castration. Braz. J. Med. Biol. Res. 2000; 33: 279-85.
26. Tanriverdi F, Gonzalez-Martinez D, Hu Y, Kelestimur F, Bouloux PM. GnRH-I and GnRH-II have differential modulatory effects on human peripheral blood mononuclear cell proliferation and interleukin-2 receptor gamma-chain mRNA expression in healthy males. Clin. Exp. Immunol. 2005; 142: 103-10.
27. Albertsen PC, Klotz L, Tombal B, Grady J, Olesen TK, Nilsson J. Cardiovascular morbidity associated with gonadotropin releasing hormone agonists and an antagonist. Eur. Urol. 2014; 65: 565-73.
28. Walker LM, Tran S, Wassersug RJ, Thomas B, Robinson JW. Patients and partners lack knowledge of androgen deprivation therapy side effects. Urol. Oncol. 2013; 31: 1098-105.
29. Sato R, Gomez Rey G, Nelson S, Pinsky B. Community-acquired pneumonia episode costs by age and risk in commercially insured US adults aged >/=50 years. Appl. Health Econ. Health Policy 2013; 11: 251-8.
30. Chon JK, Jacobs SC, Naslund MJ. The cost value of medical versus surgical hormonal therapy for metastatic prostate cancer. J. Urol. 2000; 164: 735-7.
31. Shahinian VB, Kuo YF, Freeman JL, Orihuela E, Goodwin JS. Increasing use of gonadotropin-releasing hormone agonists for the treatment of localized prostate carcinoma. Cancer 2005; 103: 1615-24.